(Q30493395)

English

Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials (English)

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Vladimir Trkulja

1

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

publication date

1 February 2010

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Croatian Medical Journal

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

51

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

1

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

61-73

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Escitalopram versus other antidepressive agents for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Escitalopram for the treatment of major depression and anxiety disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

The clinical pharmacokinetics of escitalopram

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

The improved Clinical Global Impression Scale (iCGI): development and validation in depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Imputing missing standard deviations in meta-analyses can provide accurate results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Escitalopram versus citalopram: the surprising role of the R-enantiomer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

A rating scale for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

20 June 2018

Ranking antidepressants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

[Escitalopram versus citalopram in true depression. Review of studies do not support clinically relevant differences of the effect].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

The Clinical Global Impressions scale: errors in understanding and use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

Spotlight on escitalopram in the management of major depressive disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

Efficacy of escitalopram in patients with severe depression: a pooled analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

Escitalopram: superior to citalopram or a chiral chimera?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2829184

26 November 2018

Escitalopram in the treatment of major depressive disorder: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20162747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3325/CMJ.2010.51.61

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30493395&oldid=1955342411"